絞り込み

18381

広告

「叡王戦」異例の第9局で豊島竜王勝利「二冠」に返り咲き

将棋の八大タイトルの1つ「叡王戦」の七番勝負は、2回の引き分けがあったことから「第9局」までもつれ込む異例の展開となった結果、挑戦者の豊島将之竜王(30)がタイ...

  1. [企業] RocheがInflazome...
  2. 20世紀まで残った決闘 中心地だったフラ...
  3. 森と湖が広がる北の原野に環境破壊の恐れ、...
  4. 検証プラス・新型コロナ:遅い政策、消えた...

ニュース一覧

GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

著者 Johnson PH , Weinreb NJ , Cloyd JC , Tuite PJ , Kartha RV
Mol Genet Metab.2019 Oct 23 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (48view , 0users)
The discovery that patients with Gaucher Disease (GD), a rare lysosomal storage disorder, were developing symptoms similar to Parkinson's disease (PD) led to investigation of the relationship between the two seemingly unrelated pathologies. GD, an autosomal recessive disorder, is the result of a biallelic mutation in the gene GBA1, which encodes for the enzyme glucocerebrosidase (GCase). Since the observation of its relation to PD, GBA1 mutations have become recognized as the most common genetic risk factor for development of synucleinopathies such as PD and dementia with Lewy bodies. Although the exact mechanism by which GBA1 mutations promote PD is unknown, current understanding suggests that impaired GCase inhibits lysosomal activity and decreases the overall ability of the cell to degrade proteins, specifically the neuronal protein α-synuclein. Decreased elimination of α-synuclein can lead to its abnormal accumulation and aggregation, an important component of PD development. Further understanding of how decreased GCase activity increases risk for α-synuclein pathology can assist with the development of clinical biomarkers for early detection of synucleinopathies, as well as promote novel treatments tailored for people with a GBA1 mutation. Historically, α-synuclein has not been a reliable biomarker for PD. However, recent research on α-synuclein content within exosomes, which are small vesicles released by cells that carry specific cellular cargo, has yielded promising results. Moreover, decreased GCase activity has been shown to influence exosomal contents. Exosomes have emerged as a promising new avenue for the identification of novel biomarkers and therapeutic targets aimed at with the goal of improving neuronal GCase function and limiting the development of synucleinopathies.
PMID: 31761523 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード